[03 May 2013]
Products Affected - Description
Methylprednisolone acetate injection, Sandoz
40 mg/mL, 1 mL vials (NDC 00781-3131-71)
40 mg/mL, 1 mL vials, packages of 10 (NDC 00781-3131-95)
40 mg/mL, 10 mL vials (NDC 00781-3136-70)
80 mg/mL, 1 mL vials (NDC 00781-3132-71)
80 mg/mL, 1 mL vials, packages of 10 (NDC 00781-3132-95)
80 mg/mL, 5 mL vials (NDC 00781-3137-75)
Methylprednisolone acetate injection, Teva
40 mg/mL, 1 mL vials (NDC 00703-0031-01)
40 mg/mL, 1 mL vials, packages of 25 (NDC 00703-0031-04)
Reason for the Shortage
Sandoz and Teva could not provide a reason for the shortage.
Available Products
Depo-Medrol injection, Pfizer
20 mg/mL, 5 mL vials (NDC 00009-0274-01)
40 mg/mL, 1 mL vials (NDC 00009-3073-01)
40 mg/mL, 1 mL vials, packages of 25 (NDC 00009-3073-03)
40 mg/mL, 1 mL Novaplus vials (NDC 00009-3073-22)
40 mg/mL, 1 mL Novaplus vials, packages of 25 (NDC 00009-3073-23)
40 mg/mL, 5 mL vials (NDC 00009-0280-02)
40 mg/mL, 5 mL vials, packages of 25 (NDC 00009-0280-51)
40 mg/mL, 10 mL vials (NDC 00009-0280-03)
40 mg/mL, 10 mL vials, packages of 25 (NDC 00009-0280-52)
80 mg/mL, 1 mL vials (NDC 00009-3475-01)
80 mg/mL, 1 mL vials, packages of 25 (NDC 00009-3475-03)
80 mg/mL, 1 mL Novaplus vials (NDC 00009-3475-22)
80 mg/mL 1 mL Novaplus vials, packages of 25 (NDC 00009-3475-23)
80 mg/mL 5 mL vials (NDC 00009-0306-02)
80 mg/mL 5 mL vials, packages of 25 (NDC 00009-0306-12)
Methylprednisolone acetate injection, Teva
40 mg/mL, 5 mL vials (NDC 00703-0043-01)
40 mg/mL, 10 mL vials (NDC 00703-0045-01)
80 mg/mL, 1 mL vials (NDC 00703-0051-01)
80 mg/mL, 1 mL vials, packages of 25 (NDC 00703-0051-04)
80 mg/mL, 5 mL vials (NDC 00703-0063-01)
Estimated Resupply Dates
- Sandoz has all methylprednisolone acetate injection on back order and the company cannot estimate a release date.
- Teva has methylprednisolone acetate injection 40 mg/mL 1 mL vials on back order and the company cannot estimate a release date. Teva has released all other methylprednisolone acetate injection presentations to wholesalers. Please contact your wholesaler to determine availability.
Implications for Patient Care
- FDA closed New England Compounding Company in Massachusetts due to a fungal meningitis outbreak linked to methylprednisolone acetate injections compounded by this pharmacy.
- All commercially available products contain a preservative such as myristyl gamma picolinium chloride or benzyl alcohol.
- Methylprednisolone acetate is not approved for epidural administration and contraindicated for intrathecal use.
Related Shortages
Updated
May 3, 2013; April 19, 2013; March 15, 2013; January 22, 2013; November 20, 2012; November 16, 2012; October 5, 2012; September 26, 2012; August 21, 2012; July 26, 2012; July 9, 2012; June 20, 2012; May 22, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins